210 related articles for article (PubMed ID: 33039103)
1. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.
Lapeyre-Mestre M
Therapie; 2020; 75(5):393-395. PubMed ID: 33039103
[No Abstract] [Full Text] [Related]
2. Medication-Based Treatment to Address Opioid Use Disorder.
Leshner AI; Dzau VJ
JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
[No Abstract] [Full Text] [Related]
3. Enhancing engagement between legislators and nursing to increase buprenorphine access.
Finnell DS; Schimmels J; Tierney M
Nurs Outlook; 2023; 71(4):102004. PubMed ID: 37429154
[No Abstract] [Full Text] [Related]
4. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
Balhara YP
J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
[No Abstract] [Full Text] [Related]
5. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021.
Vidyasagar N; Bunting SR; Arora VM; Ari M
JAMA; 2024 Feb; 331(6):524-526. PubMed ID: 38236586
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
Yan K
N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
[No Abstract] [Full Text] [Related]
7. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
Sigmon SC; Schwartz RP; Higgins ST
N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
[No Abstract] [Full Text] [Related]
8. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
Shover CL
Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
[No Abstract] [Full Text] [Related]
9. Buprenorphine Initiation: Low-Dose Methods #457.
Ho JJ; Jones KF; Merlin JS; Sager Z; Childers J
J Palliat Med; 2023 Jun; 26(6):867-869. PubMed ID: 37276524
[No Abstract] [Full Text] [Related]
10. Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?
Weimer MB; Fiellin DA
Addiction; 2022 Jun; 117(6):1507-1509. PubMed ID: 35032081
[No Abstract] [Full Text] [Related]
11. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.
Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW
JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972
[TBL] [Abstract][Full Text] [Related]
12. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
Roberts E; Humphreys K
Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Opioid Overdose.
Babu KM; Brent J; Juurlink DN
N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
[No Abstract] [Full Text] [Related]
14. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
Chou R; Ballantyne J; Lembke A
Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
[No Abstract] [Full Text] [Related]
15. The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis.
Lintzeris N; Hayes V; Dunlop AJ
Med J Aust; 2024 Apr; 220(6):339-340. PubMed ID: 38438113
[No Abstract] [Full Text] [Related]
16. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
17. Extended-Release Buprenorphine Receives FDA Green Light.
Harris E
JAMA; 2023 Jun; 329(24):2119. PubMed ID: 37285164
[No Abstract] [Full Text] [Related]
18. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
19. In brief: Over-the-counter Narcan nasal spray.
Med Lett Drugs Ther; 2023 May; 65(1675):72. PubMed ID: 37155252
[No Abstract] [Full Text] [Related]
20. Initial experience with subcutaneous depot buprenorphine in a medically supervised injecting facility.
Weeks A; Cogger S; Clark N
Drug Alcohol Rev; 2021 Nov; 40(7):1354-1355. PubMed ID: 33821545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
